FDA regrets that it was unable to publish this notice 15 days prior to the December 4, 1997, Circulatory System Devices Panel of the Medical Devices Advisory Committee meeting. Because the agency believes there is some urgency to bring this issue to public discussion and qualified members of the Circulatory System Devices Panel of the Medical Devices Advisory Committee were available at this time, the Commissioner concluded that it was in the public interest to hold this meeting even if there was not sufficient time for the customary 15-day public notice.

Closed Committee Deliberations: On December 4, 1997, from 9 a.m. to 5 p.m., the meeting will be closed to permit discussion and review of trade secret and/or confidential commercial information on a product development protocol. This portion of the meeting will be closed to permit discussion of this information (5 U.S.C. 552b (c)(4)).

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: November 20, 1997.

Michael A. Friedman,

Deputy Commissioner for Operations. [FR Doc. 97–31064 Filed 11–21–97; 11:12 am]

BILLING CODE 4160-01-F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Notice of Meeting of the Advisory Committee to the Director, NIH

Pursuant to Pub. L. 92–463, notice is hereby given of the meeting of the Advisory Committee to the Director, NIH, December 4, 1997, Conference Room 10, Building 31, National Institutes of Health, Bethesda, Maryland 20892.

The entire meeting will be open to the public from 8:30 a.m. to adjournment. The topics proposed for discussion include: (1) Center for Scientific Review; (2) Report from the Clinical Research Panel; (3) New Investigator Awards, Modular Awards, and Clinical Research Training; (4) Report from the Working Group on Research Tools; (5) Implementation of the Government Performance and Results Act; and (6) Report on the Review of Administrative Functions at NIH. Attendance by the public will be limited to space available.

Ms. Janice Ramsden, Special Assistant to the Deputy Director, National Institutes of Health, 1 Center Drive MSC 0159, Bethesda, Maryland 20892–0159, telephone (301) 496–0959, fax (301)

496–7451, will furnish the meeting agenda, roster of committee members, and available substantive program information upon request. Any individual who requires special assistance, such as sign language interpretation or other reasonable accommodations, should contact Ms. Ramsden no later than November 26, 1997.

Dated: November 18, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH. [FR Doc. 97–30931 Filed 11–24–97; 8:45 am] BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Closed Meeting

Pursuant to Section 10(d) of Public Law 92-463, as amended, notice is hereby given of a meeting of the President's Cancer Panel, National Cancer Institute. This meeting will be closed to the public in accordance with the provisions set forth in sec. 552b(c)(9)(B), Title 5, U.S.C. The purpose of this meeting is to plan the 1997 Final Report of the Chairman to the President and to set agendas for the upcoming 1998 panel meetings. Premature disclosure of the specific details of these discussions and recommendations would be likely to significantly frustrate the subsequent implementation of the proposed recommendations made by the Panel.

Linda Quick-Cameron, Committee Management Officer, National Cancer Institute, Executive Plaza North, Room 609, 6130 Executive Blvd., MSC 7410, Bethesda, MD 20892–7410 (301/496–5708) will provide a copy of the roster of committee members upon request. Other information pertaining to the meeting may be obtained from the contact person indicated below.

Committee Name: President's Cancer Panel.

Date: December 1, 1997.

Place: Hyatt Regency Bethesda, 1 Bethesda Metro Center, Bethesda, MD 20814

Closed: 10:30 a.m. to Adjournment. Agenda: Discussion and preparation of the 1997 Final Report of the Chairman to the President and set agendas for the 1998 meetings.

Contact Person: Maureen O. Wilson, Ph.D., Executive Secretary, National Cancer Institute, Building 31, Room 4A48, 9000 Rockville Pike, MSC 2473, Bethesda, MD 20892–2473, Telephone: (301) 496–1148.

Dated: November 6, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97–30926 Filed 11–24–97; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Meeting of the National Cancer Advisory Board and Its Subcommittees

Pursuant to the Federal Advisory Committee Act, as amended, notice is hereby given of the meeting of the National Cancer Advisory Board (Board), National Cancer Institute (NCI), and its Subcommittees on December 2– 3, 1997. The meetings of the Board and its Subcommittees will be open to the public as indicated below. Attendance by the public will be limited to space available.

A portion of the Board meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(6) and 552b(c)(9)(B), Title 5 U.S.C. and section 10(d) of the Federal Advisory Committee Act, as amended, for discussions pertaining to NCI personnel and programmatic issues. These discussions could reveal information of a personal nature where disclosure would constitute a clearly unwarranted invasion of personal privacy and would be likely to significantly frustrate the subsequent implementation of personnel and programmatic recommendations made during these discussions.

The Committee Management Office, National Cancer Institute, National Institutes of Health, Executive Plaza North, Room 609, 6130 Executive Boulevard, MSC 7410, Bethesda, Maryland 20892–7410, (301) 496–5708 will provide summaries of the meetings and rosters of the Board members, upon request.

Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should contact Mrs. Linda Quick-Cameron, Committee Management Officer, at (301) 496–5708 in advance of the meeting.

Name of Committee: National Cancer Advisory Board.

Contact Person: Dr. Marvin R. Kalt, Executive Secretary, National Cancer Institute, NIH, Executive Plaza North, Room